Claims
- 1. A method for treating the surface of a medical device comprising:(a) forming a medical device from a material comprising monomeric units having reactive functionalities selected from the group consisting of azlactone, carboxylic acid, amine, hydroxy and epoxy functionalities, and combinations thereof; (b) forming a hydrophilic reactive polymer having complementary reactive functionalities along the polymer chain, said complementary reactive functionalities selected from the group consisting of azlactone, isocyanate, acid anhydride, epoxy, hydroxy, primary amine, secondary amine and carboxylic acid functionalities, and combinations thereof, wherein: when the hydrophilic reactive polymer comprises hydroxy or amine complementary reactive functionalities, the medical device monomeric units comprise azlactone reactive functionalities, or when the hydrophilic reactive polymer comprises carboxylic acid complementary functionality, the medical device monomeric units comprise epoxy reactive functionalities; (c) reacting the hydrophilic reactive polymer of (b) having complementary reactive functionalities along the polymer chain with said medical device monomeric unit reactive functionalities on or near the surface of the medical device of (a), thus forming a biocompatible surface on the medical device; (d) removing the biocompatible surface of step (c); and (e) repeating steps (b) and (c) to form a renewed biocompatible surface on said medical device having properties similar to the original biocompatible surface of step (c).
- 2. The method of claim 1, wherein the medical device is a silicone contact lens or intraocular lens and the hydrophilic reactive polymer is uncolored.
- 3. The method of claim 1, wherein the medical device is a silicone hydrogel, continuous-wear contact lens.
- 4. The method of claim 3 wherein said removing step (d) further comprises abrading said biocompatible surface with an abrasive particulate in an aqueous carrier solution.
- 5. The method of claim 4, wherein said abrasive particulate comprises silica or alumina.
- 6. The method of claim 1, wherein the hydrophilic reactive polymer comprises 1 to 100 mole percent of monomeric units having said reactive functionalities.
- 7. The method of claim 1, wherein the hydrophilic reactive polymer comprises 0 to 99 mole percent of monomeric units that are derived from non-reactive hydrophilic monomers.
- 8. The method of claim 1, wherein the polymer comprises 50 to 95 mole percent of monomeric units derived from non-reactive hydrophilic monomers selected from the group consisting of acrylamides, lactones, poly(alkylenepoxy)methacrylates, methacrylic acid or hydroxyalkyl methacrylates and 5 to 50 percent of monomeric units derived from functionally reactive monomers selected from the group consisting of epoxy, azlactone, and anhydride containing monomers.
- 9. The method of claim 1, wherein the medical device comprises a silicone hydrogel that is a polymerization product of a mixture comprising a silicon-containing monomer and a hydrophilic monomer.
- 10. The method of claim 1, wherein the hydrophilic reactive polymer comprises 0 to 35 mole percent monomeric units derived from hydrophobic monomers.
- 11. The method of claim 1, wherein the hydrophilic polymer comprises oxazolinone moieties having the following formula: wherein R3 and R4 independently can be an alkyl group having 1 to 14 carbon atoms; a cycloalkyl group having 3 to 14 carbon atoms; an aryl group having 5 to 12 ring atoms; an arenyl group having 6 to 26 carbon atoms; and 0 to 3 heteroatoms selected from S, N, and nonperoxidic 0; or R3 and R4 taken together with the carbon to which they are joined can form a carbocyclic ring containing 4 to 12 ring atoms, and n is an integer 0 or 1.
- 12. The method of claim 11, wherein the polymer comprises the reaction product of a mixture of monomers comprising the monomer represented by the general formula: where R1 and R2 independently denote a hydrogen atom or a lower alkyl radical with one to six carbon atoms, and R3 and R4 independently denote alkyl radicals with one to six carbon atoms or a cycloalkyl radicals with 5 or 6 carbon atoms.
- 13. The method of claim 12, wherein the monomer is selected from the group consisting of 2-isopropenyl-4,4-dimethyl-2-oxazolin-5-one and 2-vinyl-4,4-dimethyl-2-oxazolin-5-one.
- 14. The method of claim 11, in the medical device is dipped in a solution comprising at least one hydrophilic reactive polymer in the absence of a coloring substance.
- 15. The method of claim 1 wherein said removing step (d) further comprises abrading said biocompatible surface.
- 16. The method of claim 1, wherein the medical device is a rigid contact lens.
- 17. The method of claim 16, wherein the rigid contact lens is a rigid-gas-permeable contact lens.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is related by subject matter to commonly-assigned U.S. application Ser. No. 09/315,620, filed May 20, 1999.
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
4734475 |
Goldenberg et al. |
Mar 1988 |
A |
5177165 |
Valint, Jr. et al. |
Jan 1993 |
A |
5206298 |
Kawaguchi |
Apr 1993 |
A |
5219965 |
Valint, Jr. et al. |
Jun 1993 |
A |
5708050 |
Nakada et al. |
Jan 1998 |
A |
6008170 |
Tanaka et al. |
Dec 1999 |
A |
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9300391 |
Jan 1993 |
WO |